45.2 Hematuria Workup & Glomerulonephritis

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

45.2 Hematuria Workup & Glomerulonephritis

Key Takeaways Explain This Topic AI

Gross hematuria in an adult carries a 10% to 20% risk of underlying urothelial or renal malignancy and mandates a complete diagnostic urological evaluation including multiphasic CT urography and cystoscopy, regardless of whether the bleeding is transient, self-limiting, or provoked by anticoagulants.

Microscopic hematuria is strictly defined by the American Urological Association (AUA) as >=3 red blood cells per high-power field (RBCs/HPF) on microscopic examination of a single properly collected clean-catch midstream urine specimen; dipstick heme positivity alone does not constitute microscopic hematuria and must always be confirmed microscopically.

Glomerular bleeding is differentiated from lower urological bleeding by the presence of dysmorphic RBCs (>80%), pathognomonic red blood cell casts, significant proteinuria (>500 mg/day or UPCR >0.5), and cola-colored urine without gross blood clots; the presence of gross blood clots invariably indicates non-glomerular, lower urinary tract bleeding.

Under the AUA 2020 Risk-Stratified Guideline for microscopic hematuria, low-risk patients undergo shared decision-making for repeat urinalysis versus cystoscopy/renal ultrasound, intermediate-risk patients undergo renal ultrasound plus cystoscopy, and high-risk patients (men/women >=60 years, >30 pack-years, >25 RBCs/HPF, or prior gross hematuria) require multiphasic CT urography and cystoscopy.

IgA nephropathy typically presents with synpharyngitic gross hematuria (within 24 to 48 hours of an acute upper respiratory infection) with completely normal complement levels, whereas post-streptococcal glomerulonephritis (PSGN) presents after a 1- to 3-week latent period following pharyngitis (or 3 to 6 weeks post-impetigo) with depressed complement C3 and elevated ASO or anti-DNase B titers.

Last updated: September 2026

Definitions, Epidemiology & Clinical Significance of Hematuria

Hematuria is one of the most frequent reasons for referral to nephrology and urology. In the ambulatory setting, clinicians must distinguish macroscopic (gross) hematuria from microscopic hematuria, exclude benign mimics and pseudohematuria, and localize bleeding to either the nephron (glomerular) or the urinary tract (non-glomerular).

Gross (Macroscopic) Hematuria

Definition : Visible pink, bright red, or tea/brown discoloration of the urine recognized by the naked eye.

Malignancy Risk : In adult patients presenting with gross hematuria, the risk of harboring an underlying urothelial or renal malignancy is 10% to 20% (most commonly urothelial bladder carcinoma, followed by renal cell carcinoma, ureteral urothelial carcinoma, and prostate cancer).

Mandatory Clinical Directive : A single episode of gross hematuria mandates a complete, comprehensive urological evaluation in all adults, regardless of whether the bleeding is painless, self-limiting, transient, or occurs in a patient on therapeutic anticoagulation or antiplatelet therapy. Anticoagulants unmask, but do not cause, neoplastic bleeding.

Microscopic Hematuria

AUA / SUO Guideline Definition : The 2020 American Urological Association (AUA) and Society of Urologic Oncology (SUO) guideline strictly defines microscopic hematuria as >=3 red blood cells per high-power field (RBCs/HPF) on microscopic examination of a single, properly collected, clean-catch unspun midstream urine specimen.

The Pitfall of Urine Dipstick Testing : The reagent strip detects the pseudoperoxidase activity of the heme moiety. Although dipstick testing boasts a high sensitivity (>90%), its specificity is poor (65% to 90%).

Important

AUA GUIDELINE MANDATE: DIPSTICK ALONE IS INSUFFICIENT A positive urine dipstick for heme/blood does NOT establish the diagnosis of microscopic hematuria. A positive dipstick must ALWAYS be confirmed with formal microscopic urinalysis demonstrating >=3 RBCs/HPF before initiating an extensive diagnostic evaluation. If microscopy reveals <3 RBCs/HPF, the workup for hematuria should NOT be pursued.

Causes of Pseudohematuria (False Positives on Dipstick or Red Urine)

Clinicians must systematically rule out benign pigments, endogenous molecules, and medications that alter urine color: DIFFERENTIAL DIAGNOSIS OF PSEUDOHEMATURIA

Condition / Substance Dipstick Heme Urine Microscopy Mechanism / Clinical Features
═══════════════════════════════════════════════════════════════════════════════════════════
Myoglobinuria POSITIVE (4+) 0 to 1 RBCs/HPF • Rhabdomyolysis (trauma, statins,
(Endogenous heme) extreme exertion, heat stroke)
Serum CK markedly elevated (>5000)
Pigmented granular / brown casts

Hemoglobinuria POSITIVE (4+) 0 to 1 RBCs/HPF • Intravascular hemolysis (PNH, G6PD,
(Free hemoglobin) prosthetic heart valves, DIC)
Low haptoglobin, elevated LDH

Dietary Pigments NEGATIVE 0 RBCs/HPF • Betaturia (beets in non-metabolizers)
(Anthocyanins, betalain) • Blackberries, rhubarb

Pharmacologic Agents:

Rifampin NEGATIVE 0 RBCs/HPF • Bright orange/red urine, tears, sweat
Phenazopyridine NEGATIVE 0 RBCs/HPF • Bright orange/red urine; interferes
(Pyridium) with dipstick colorimetric readings
Sulfasalazine, Senna NEGATIVE 0 RBCs/HPF • Orange to red-brown discoloration
Metronidazole NEGATIVE 0 RBCs/HPF • Dark brown / tea-colored urine
═══════════════════════════════════════════════════════════════════════════════════════════
Glomerular vs. Non-Glomerular (Urological) Hematuria

The fundamental branch point in evaluating confirmed hematuria is determining whether the bleeding originates from the glomerulus (nephron) or from the extraglomerular urinary tract (calyces, renal pelvis, ureters, bladder, prostate, or urethra). LOCALIZATION: GLOMERULAR VS. NON-GLOMERULAR BLEEDING

Clinical Feature Glomerular Origin Non-Glomerular (Urological)
═══════════════════════════════════════════════════════════════════════════════════════════
Urine Color • Smoky, brown, cola-, or • Bright red, pink, or frank
tea-colored bloody urine

Blood Clots • ABSENT (clots cannot pass • PRESENT (pathognomonic for
through glomerular barrier; lower tract bleeding from bladder,
urokinase degrades fibrin) prostate, ureter, or pelvis)

RBC Morphology • DYSMORPHIC RBCs (>80%) • ISOMORPHIC RBCs (>80%)
Acanthocytes (ring cells with Uniform, smooth, biconcave
protruding blebs / Mickey Mouse disc-shaped red blood cells
ears >5% is pathognomonic)

Urinary Casts • RED BLOOD CELL CASTS • ABSENT (may see normal
(pathognomonic for GN); hyaline casts)
Pigmented granular casts

Proteinuria • SIGNIFICANT (>500 mg/day; • ABSENT or TRACE (<500 mg/day;
UPCR >0.5; dipstick >=2+) protein is proportional to blood)

Associated Findings • Hypertension, periorbital / • Flank colic (stone), dysuria,
pretibial edema, oliguria, fever, palpable mass, or completely
elevated serum creatinine asymptomatic (malignancy)
═══════════════════════════════════════════════════════════════════════════════════════════
Clinical Implications of Localization

Glomerular Bleeding Identified : The patient requires a medical nephrology evaluation (serologic immunological testing, quantitation of 24-hour proteinuria or spot protein-to-creatinine ratio, and potential percutaneous renal biopsy). CT urography and cystoscopy are not indicated unless there is concomitant urological disease.

Non-Glomerular Bleeding Identified : The patient requires a structural urological workup to rule out urothelial carcinomas, renal cell carcinoma, nephrolithiasis, and benign prostatic hyperplasia.

AUA/SUO 2020 Risk-Stratified Guideline for Microscopic Hematuria

The American Urological Association (AUA) and Society of Urologic Oncology (SUO) revolutionized the evaluation of microscopic hematuria by replacing the historical "one-size-fits-all" aggressive imaging approach with an evidence-based, risk-stratified paradigm for adults >=35 years of age. AUA 2020 MICROSCOPIC HEMATURIA RISK STRATIFICATION

Risk Category Patient Characteristics & Criteria Recommended Diagnostic Action
═══════════════════════════════════════════════════════════════════════════════════════════

LOW RISK Must meet ALL of the following: • Shared Decision-Making:

Women <50 years; Men <40 years 1) Repeat UA in 6 months, OR
Smoking history: <10 pack-years 2) Renal Ultrasound + Cystoscopy
3 to 10 RBCs/HPF on microscopy • Multiphasic CTU is NOT indicated
No additional malignancy risk factors

INTERMEDIATE Meets ANY of the following: • RENAL ULTRASOUND +
RISK • Women 50 to 59 years; Men 40 to 59 years • CYSTOSCOPY (Rigid or Flexible)
Smoking history: 10 to 30 pack-years • Avoids ionizing radiation of CT
11 to 25 RBCs/HPF on microscopy while maintaining high sensitivity

Low-risk patient with additional risks:

Prior pelvic radiation
Cyclophosphamide exposure
Occupational dyes / aromatic amines
Chronic indwelling Foley catheter

HIGH RISK Meets ANY of the following: • MULTIPHASIC CT UROGRAPHY (CTU)
All patients >=60 years (Non-contrast, nephrographic,
Smoking history: >30 pack-years and excretory/delayed phases)
>25 RBCs/HPF on microscopy • PLUS CYSTOSCOPY
History of GROSS HEMATURIA • Gold standard comprehensive workup
═══════════════════════════════════════════════════════════════════════════════════════════
Detailed Imaging Protocols

Multiphasic CT Urography (CTU) : The imaging modality of choice for high-risk patients. CTU utilizes a three-phase acquisition:

Non-contrast Phase : Identifies nephrolithiasis and calcifications.

Nephrographic Phase (90-100 sec post-IV contrast) : Maximally opacifies the renal parenchyma, optimizing detection of renal cell carcinoma and cortical lesions.

Excretory / Delayed Phase (10-15 min post-contrast) : Iodinated contrast opacifies the urinary collecting system, allowing detailed visualization of filling defects in the renal calyces, renal pelvis, and ureters (urothelial carcinoma).

Renal Ultrasound : Preferred in intermediate-risk patients to eliminate radiation exposure. Accurately identifies renal masses, hydronephrosis, and cysts, but cannot reliably detect small urothelial tumors of the ureters or bladder.

Cystoscopy : Transurethral endoscopic visualization of the bladder lumen, bladder neck, and urethra. Cystoscopy is the single most sensitive method for diagnosing bladder urothelial carcinoma; cross-sectional imaging (CT or ultrasound) cannot reliably rule out flat, non-muscle-invasive bladder tumors or carcinoma in situ (CIS).

Contraindications to Iodinated Contrast : In patients with severe renal impairment (eGFR <30 mL/min) or severe contrast allergy, multiphasic CTU cannot be performed. Alternative protocols combine Renal Ultrasound or Non-Contrast CT with Bilateral Retrograde Pyelography (RPG) performed under fluoroscopy during cystoscopy.

Glomerulonephritis & Nephritic Syndrome

When urinalysis reveals glomerular bleeding (dysmorphic RBCs, RBC casts, and proteinuria), the clinical syndrome of Acute Glomerulonephritis (Nephritic Syndrome) must be suspected.

The Cardinal Clinical Tetrad

Nephritic syndrome is characterized by an inflammatory destruction of the glomerular filtration barrier, presenting with:

Hematuria : Smoky, cola-colored urine with microscopic dysmorphic RBCs and pathognomonic red blood cell casts.

Hypertension : Impaired glomerular filtration of sodium and water triggers extracellular volume expansion, suppression of plasma renin activity, and systemic hypertension.

Edema : Secondary to sodium and water retention. Classically presents as periorbital puffiness/edema upon awakening in the morning (loose subcutaneous tissues) and dependent pretibial pitting edema in the evening.

Oliguria & Acute Kidney Injury : Abrupt decline in GFR leading to oliguria (<400-500 mL urine/24 hr) and rapidly escalating serum BUN and creatinine. NEPHRITIC SYNDROME VS. NEPHROTIC SYNDROME

Feature Nephritic Syndrome Nephrotic Syndrome
═══════════════════════════════════════════════════════════════════════════════════════════
Pathophysiology Glomerular INFLAMMATION & necrosis PODOCYTE EFFACEMENT / charge defect
Urine Sediment ACTIVE: Dysmorphic RBCs, RBC CASTS BLAND: Oval fat bodies, Maltese cross
Proteinuria Sub-nephrotic (<3.5 g/24 hr; 0.5-3g) MASSIVE: Nephrotic (>3.5 g/24 hr)
Serum Albumin Normal or mildly depressed SEVERELY DEPRESSED (<3.0 g/dL)
Edema Mild to moderate (periorbital) SEVERE, GENERALIZED (Anasarca, ascites)
Blood Pressure HYPERTENSION (volume expansion) Normal or low (intravascular depletion)
Lipids Normal HYPERLIPIDEMIA (elevated LDL/chol)
═══════════════════════════════════════════════════════════════════════════════════════════
Major Etiologies, Serologic Profiles & Clinical Pearls

Primary care physicians must master the clinical distinctions, serological profiles, complement patterns, and management strategies for the five major glomerulonephritides. SEROLOGIC & COMPLEMENT PROFILES IN GLOMERULONEPHRITIS

Etiology Complement C3 / C4 Diagnostic Serology & Pathology Markers
═══════════════════════════════════════════════════════════════════════════════════════════
Post-Streptococcal LOW C3 (Normal/Low C4) • Elevated ASO (post-pharyngitis) & Anti-DNase B
GN (PSGN) Normalizes in 6-8 weeks • Subepithelial humps on EM; "starry sky" IgG/C3

IgA Nephropathy NORMAL C3 & C4 • Galactose-deficient IgA1; Normal complement
(Berger Disease) • Mesangial IgA & C3 deposition on IF

Anti-GBM Disease NORMAL C3 & C4 • Serum Anti-GBM antibodies (alpha-3 chain Col IV)
(Goodpasture) • Bright LINEAR IgG along GBM on IF

ANCA-Associated NORMAL C3 & C4 • GPA: c-ANCA / PR3-ANCA (sinus/lung cavitary)
Vasculitis • MPA: p-ANCA / MPO-ANCA (pulmonary-renal)
Pauci-immune crescentic GN (NO immune deposits)

Lupus Nephritis LOW C3 & LOW C4 • ANA positive (>98%); Anti-dsDNA (mirrors flare)
(SLE Class III/IV) (Classical pathway) • "Full house" immunofluorescence (IgG, A, M, C3, C1q)
═══════════════════════════════════════════════════════════════════════════════════════════
1. Post-Streptococcal Glomerulonephritis (PSGN)

Pathophysiology : Immune complex-mediated glomerulonephritis triggered by nephritogenic strains of Group A Beta-Hemolytic Streptococcus (GAS, Streptococcus pyogenes ). Soluble streptococcal antigens (speB) deposit in the glomerular basement membrane, fixing complement and attracting neutrophils.

Latent Period :

1 to 3 weeks (average 10 to 14 days) following streptococcal pharyngitis.

3 to 6 weeks following streptococcal impetigo / pyoderma.

Laboratory Findings :

Hypocomplementemia : Markedly depressed serum C3 , with normal or mildly depressed C4. Serum C3 levels MUST return to normal within 6 to 8 weeks . If hypocomplementemia persists beyond 8 weeks, alternative diagnoses (membranoproliferative GN or lupus nephritis) must be investigated.

Serology : Elevated Antistreptolysin O (ASO) titer (positive in >80% following pharyngitis, but unreliable following skin infections) and elevated Anti-DNase B titer (positive in >90% of both pharyngeal and impetigo-associated cases).

Biopsy : Electron microscopy demonstrates pathognomonic large subepithelial electron-dense "humps" ; immunofluorescence shows granular "starry sky" or "garland" deposition of IgG and C3.

Management & Prognosis : Supportive therapy. Sodium and fluid restriction, loop diuretics (furosemide) for volume overload and hypertension, and blood pressure control. Antibiotic therapy (penicillin) is given to eradicate residual pharyngeal or cutaneous streptococci to prevent transmission, but antibiotics do NOT alter or shorten the course of glomerulonephritis . Prognosis is exceptionally favorable in pediatric patients (>95% complete clinical recovery); adults experience higher rates of persistent microscopic hematuria and hypertension (~20%).

2. IgA Nephropathy (Berger Disease)

Epidemiology : The most common primary glomerulonephritis worldwide , with marked predilection for young adults (males > females, peak incidence 15 to 35 years; high prevalence in East Asian and Caucasian populations).

Pathophysiology : Multi-hit hypothesis: Genetically driven overproduction of galactose-deficient IgA1 (Gd-IgA1) . Host IgG autoantibodies recognize Gd-IgA1, forming circulating immune complexes that deposit in the glomerular mesangium, stimulating mesangial cell proliferation, matrix expansion, and cytokine release.

Classic Clinical Presentation : Recurrent episodes of painless, macroscopic, cola-colored hematuria that occur synchronously or within 24 to 48 hours of an acute upper respiratory tract infection or gastrointestinal viral illness ("synpharyngitic hematuria").

Important
HIGH-YIELD CLINICAL DISTINCTION: PSGN VS. IgA NEPHROPATHY

IgA Nephropathy : Synpharyngitic hematuria (onset within 1 to 2 days of illness onset). Complement C3 and C4 levels are COMPLETELY NORMAL .

PSGN : Post-infectious hematuria with a distinct latent period (1 to 3 weeks post-pharyngitis, 3 to 6 weeks post-impetigo) . Complement C3 is DEPRESSED .

Systemic Counterpart : Henoch-Schönlein Purpura (IgA Vasculitis) represents the identical mesangial IgA nephropathy associated with a systemic small-vessel leukocytoclastic vasculitis, presenting with non-thrombocytopenic palpable purpura (buttocks/lower extremities), severe colicky abdominal pain, and arthralgias.

Management : Blood pressure optimization (<120 mmHg systolic) using maximal tolerated doses of ACE inhibitors or ARBs. SGLT2 inhibitors (dapagliflozin/empagliflozin) reduce chronic kidney disease progression. In patients with high risk of progression (persistent proteinuria >1 g/day despite 3 months of optimized supportive therapy), targeted-release oral budesonide (Tarpeyo) or a 6-month course of systemic corticosteroids is indicated.

3. Anti-Glomerular Basement Membrane (Anti-GBM) Disease / Goodpasture Syndrome

Pathophysiology : Severe autoimmune disease caused by circulating autoantibodies directed against the non-collagenous (NC1) domain of the alpha-3 chain of Type IV collagen in basement membranes.

Clinical Presentation : Rapidly progressive glomerulonephritis (RPGN) with acute, catastrophic oliguric renal failure. When accompanied by pulmonary alveolar hemorrhage (hemoptysis, dyspnea, bilateral diffuse alveolar infiltrates on chest imaging, iron-deficiency anemia), it is termed Goodpasture Syndrome .

Diagnostic Serology : High-titer serum anti-GBM antibodies (sensitivity and specificity >95% to 98%). Complement C3 and C4 levels are normal.

Renal Biopsy : Pathognomonic bright, smooth, continuous LINEAR deposition of IgG and C3 along the glomerular basement membrane on direct immunofluorescence, with extensive crescent formation (>50% of glomeruli) on light microscopy.

Emergent Management : Anti-GBM disease is a true medical emergency. Delay leads to irreversible fibrous crescents and dialysis dependence within days. Immediate treatment mandates:

Plasmapheresis (Plasma Exchange) : Daily or alternate-day sessions for 14 days to directly remove circulating pathogenic anti-GBM autoantibodies.

High-Dose Immunosuppression : Pulse IV methylprednisolone (1 g daily x 3 days) followed by oral prednisone PLUS oral or IV cyclophosphamide to suppress de novo antibody synthesis.

4. ANCA-Associated Vasculitis (Pauci-Immune Crescentic GN)

Pathophysiology : Systemic necrotizing small-vessel vasculitis characterized by circulating Anti-Neutrophil Cytoplasmic Antibodies (ANCA) that activate primed neutrophils, causing endothelial damage and necrotizing crescentic glomerulonephritis with an absence or paucity of immune complex deposition ( "pauci-immune" ).

Granulomatosis with Polyangiitis (GPA, formerly Wegener) : Strongly associated with c-ANCA / anti-Proteinase 3 (PR3-ANCA) (>80% to 90%). Characterized by upper respiratory tract destruction (chronic refractory sinusitis, otitis media, nasal crusting, saddle-nose deformity), pulmonary necrotizing granulomas and cavitary lesions, and crescentic GN.

Microscopic Polyangiitis (MPA) : Strongly associated with p-ANCA / anti-Myeloperoxidase (MPO-ANCA) (>70% to 80%). Presents as a pulmonary-renal syndrome (alveolar hemorrhage and rapidly progressive GN) without granulomatous inflammation or upper airway involvement.

Management : Rapid induction with high-dose corticosteroids combined with Rituximab (anti-CD20 B-cell depleting monoclonal antibody) or cyclophosphamide. Avacopan (oral complement C5a receptor antagonist) is approved as an adjunctive steroid-sparing agent.

5. Lupus Nephritis

Pathophysiology : Autoimmune immune-complex deposition in systemic lupus erythematosus (SLE), activating the classical complement cascade.

Diagnostic Markers : Positive ANA (>98%), elevated anti-double-stranded DNA (anti-dsDNA) (antibody titers correlate directly with renal disease activity and impending renal flares), anti-Smith antibodies, and profoundly low C3 and C4 levels (classical pathway consumption).

Biopsy Classification : Renal biopsy is mandatory to guide therapy. Class III (focal proliferative) and Class IV (diffuse proliferative—most common and most severe) carry high risk of end-stage renal disease. Induction requires high-dose corticosteroids plus either Mycophenolate Mofetil (MMF) or IV cyclophosphamide, alongside universal background hydroxychloroquine .